Compare Fox Corp Class A (FOXA) vs Moderna, Inc. (MRNA) Price & Performance

Fox Corporation (FOXA) trades at $62.68, down slightly by 0.03% on the day. The stock shows a bullish technical signal with strong earnings beats in recent quarters, including Q2 2026 EPS of $1.79 versus $1.44 expected. Revenue grew to $16.30 billion in 2025, with a net income margin of 13.88%. Key developments include the pending $22 billion acquisition of Roku, which is under DOJ review, and a dividend payment scheduled for September 2026.

The outlook is positive with a consensus price target of $72.00, implying 15% upside. Strengths include robust cash flow and analyst support, but risks involve regulatory scrutiny of the Roku deal and a projected decline in 2026 net income. The stock presents a value opportunity with a P/E of 16.55, though investors should monitor deal progression and earnings sustainability.

Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.

Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.